In a pair of promising developments today, researchers from Oxford University and another group from China reported in The Lancet that two different adenovirus-vectored COVID-19 vaccines prompted an immune response and appeared to be safe, paving the way for efficacy trials.Meanwhile, the global COVID-19 total passed 14.5 million today and is at 14,604,077 cases with 608,487 deaths, according to the Johns Hopkins online dashboard.Vaccines prompted antibody and T-cell responsesThe publication of the two studies today brought the number of peer-reviewed COVID-19 vaccine trials to three.
They come just 5 days after scientists reported that an mRNA vaccine developed by Moderna, with support from the US National Institute of Allergy and